How Rubius Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:RUBY Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 22
0
-180
31
96
30 Sep 22
0
-215
44
135
30 Jun 22
0
-201
48
149
31 Mar 22
0
-207
52
152
31 Dec 21
0
-197
53
142
30 Sep 21
0
-182
53
127
30 Jun 21
0
-174
53
118
31 Mar 21
0
-162
51
108
31 Dec 20
0
-168
50
116
30 Sep 20
0
-172
51
121
30 Jun 20
0
-178
54
126
31 Mar 20
0
-179
56
128
31 Dec 19
0
-163
57
112
30 Sep 19
0
-146
55
98
30 Jun 19
0
-126
53
79
31 Mar 19
0
-107
48
63
31 Dec 18
0
-89
40
52
30 Sep 18
0
-80
38
42
30 Jun 18
0
-65
31
34
31 Mar 18
0
-54
26
27
31 Dec 17
0
-45
22
21
Quality Earnings: RUBY is currently unprofitable.
Growing Profit Margin: RUBY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RUBY's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare RUBY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RUBY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: RUBY has a negative Return on Equity (-1187.4%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/01/03 22:53
End of Day Share Price
2023/12/29 00:00
Earnings
2022/12/31
Annual Earnings
2022/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rubius Therapeutics, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.